161 related articles for article (PubMed ID: 37126937)
21. MALT1 activation by TRAF6 needs neither BCL10 nor CARD11.
Bardet M; Seeholzer T; Unterreiner A; Woods S; Krappmann D; Bornancin F
Biochem Biophys Res Commun; 2018 Nov; 506(1):48-52. PubMed ID: 30336982
[TBL] [Abstract][Full Text] [Related]
22. Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation.
Howes A; O'Sullivan PA; Breyer F; Ghose A; Cao L; Krappmann D; Bowcock AM; Ley SC
Biochem J; 2016 Jun; 473(12):1759-68. PubMed ID: 27071417
[TBL] [Abstract][Full Text] [Related]
23. The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-κB signalling.
Klein T; Fung SY; Renner F; Blank MA; Dufour A; Kang S; Bolger-Munro M; Scurll JM; Priatel JJ; Schweigler P; Melkko S; Gold MR; Viner RI; Régnier CH; Turvey SE; Overall CM
Nat Commun; 2015 Nov; 6():8777. PubMed ID: 26525107
[TBL] [Abstract][Full Text] [Related]
24. Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice.
Baens M; Stirparo R; Lampi Y; Verbeke D; Vandepoel R; Cools J; Marynen P; de Bock CE; Bornschein S
Eur J Immunol; 2018 Oct; 48(10):1728-1738. PubMed ID: 30025160
[TBL] [Abstract][Full Text] [Related]
25. Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases.
Zhang YY; Peng J; Luo XJ
Biochem Pharmacol; 2022 Apr; 198():114977. PubMed ID: 35218741
[TBL] [Abstract][Full Text] [Related]
26. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
Seshadri MR; Melnick AM
Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
[TBL] [Abstract][Full Text] [Related]
27. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains.
Düwel M; Welteke V; Oeckinghaus A; Baens M; Kloo B; Ferch U; Darnay BG; Ruland J; Marynen P; Krappmann D
J Immunol; 2009 Jun; 182(12):7718-28. PubMed ID: 19494296
[TBL] [Abstract][Full Text] [Related]
28. Assignment of IVL-Methyl side chain of the ligand-free monomeric human MALT1 paracaspase-IgL
Han X; Levkovets M; Lesovoy D; Sun R; Wallerstein J; Sandalova T; Agback T; Achour A; Agback P; Orekhov VY
Biomol NMR Assign; 2022 Oct; 16(2):363-371. PubMed ID: 36094731
[TBL] [Abstract][Full Text] [Related]
29. MALT1 cleaves the E3 ubiquitin ligase HOIL-1 in activated T cells, generating a dominant negative inhibitor of LUBAC-induced NF-κB signaling.
Elton L; Carpentier I; Staal J; Driege Y; Haegman M; Beyaert R
FEBS J; 2016 Feb; 283(3):403-12. PubMed ID: 26573773
[TBL] [Abstract][Full Text] [Related]
30. Molecular architecture and regulation of BCL10-MALT1 filaments.
Schlauderer F; Seeholzer T; Desfosses A; Gehring T; Strauss M; Hopfner KP; Gutsche I; Krappmann D; Lammens K
Nat Commun; 2018 Oct; 9(1):4041. PubMed ID: 30279415
[TBL] [Abstract][Full Text] [Related]
31. Normal lymphocyte homeostasis and function in MALT1 protease-resistant HOIL-1 knock-in mice.
Skordos I; Driege Y; Haegman M; Kreike M; Staal J; Demeyer A; Beyaert R
FEBS J; 2023 Apr; 290(8):2032-2048. PubMed ID: 36479846
[TBL] [Abstract][Full Text] [Related]
32. MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.
Afonina IS; Elton L; Carpentier I; Beyaert R
FEBS J; 2015 Sep; 282(17):3286-97. PubMed ID: 25996250
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Potential of Targeting Malt1-Dependent TCR Downstream Signaling to Promote the Survival of MHC-Mismatched Allografts.
Govender L; Mikulic J; Wyss JC; Gaide O; Thome M; Golshayan D
Front Immunol; 2020; 11():576651. PubMed ID: 33042160
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.
Ma Y; Liao Z; Xu Y; Zhong Z; Wang X; Zhang F; Chen S; Yang L; Luo G; Huang X; Huang S; Wu X; Li Y
Eur J Med Res; 2014 Nov; 19(1):62. PubMed ID: 25384343
[TBL] [Abstract][Full Text] [Related]
35. Regulation of NF-κB signaling by caspases and MALT1 paracaspase.
Staal J; Bekaert T; Beyaert R
Cell Res; 2011 Jan; 21(1):40-54. PubMed ID: 21119681
[TBL] [Abstract][Full Text] [Related]
36. MALT1 Proteolytic Activity Suppresses Autoimmunity in a T Cell Intrinsic Manner.
Demeyer A; Skordos I; Driege Y; Kreike M; Hochepied T; Baens M; Staal J; Beyaert R
Front Immunol; 2019; 10():1898. PubMed ID: 31474984
[TBL] [Abstract][Full Text] [Related]
37. Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival.
Bidère N; Ngo VN; Lee J; Collins C; Zheng L; Wan F; Davis RE; Lenz G; Anderson DE; Arnoult D; Vazquez A; Sakai K; Zhang J; Meng Z; Veenstra TD; Staudt LM; Lenardo MJ
Nature; 2009 Mar; 458(7234):92-6. PubMed ID: 19118383
[TBL] [Abstract][Full Text] [Related]
38. MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.
McAuley JR; Bailey KM; Ekambaram P; Klei LR; Kang H; Hu D; Freeman TJ; Concel VJ; Hubel NE; Lee JL; Klei HB; Cheng J; Sekar P; Bridwell RE; Covic L; Lucas PC; McAllister-Lucas LM
Oncogene; 2019 Dec; 38(49):7384-7398. PubMed ID: 31420608
[TBL] [Abstract][Full Text] [Related]
39. The Paracaspase MALT1 in Cancer.
Gomez Solsona B; Schmitt A; Schulze-Osthoff K; Hailfinger S
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203553
[TBL] [Abstract][Full Text] [Related]
40. The LUBAC participates in lysophosphatidic acid-induced NF-κB activation.
Douanne T; Chapelier S; Rottapel R; Gavard J; Bidère N
Cell Immunol; 2020 Jul; 353():104133. PubMed ID: 32450431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
